|
PRIMARY
LYMPHOMA OF THE PROSTATE: A RARE CAUSE OF URINARY OBSTRUCTION
(
Download pdf )
ALBERTO A. ANTUNES,
MARCOS DALL’OGLIO, MIGUEL SROUGI
Discipline
of Urology, Paulista School of Medicine, Federal University of São
Paulo (UNIFESP),
São Paulo, Brazil
ABSTRACT
Primary
lymphoma of the prostate is rare. It represents 0.09% of prostate neoplasias.
The authors report the case of a 42-year old patient presenting urinary
obstruction and renal failure due to primary lymphoma of the prostate.
We discuss the clinical manifestations of
this disease, emphasizing that systemic chemotherapy represents the initial
and preferential therapeutic method
Key
words: prostatic neoplasms; lymphoma; ureteral obstruction
Int Braz J Urol. 2004; 30: 410-2
INTRODUCTION
Primary
lymphoma of the prostate is rare. It represents 0.09% of prostate neoplasias
and 0.1% of all non-Hogdkin lymphomas (1). Secondary involvement of the
gland is the most common presentation in such cases (2).
The authors report the case of a patient
presenting infravesical obstruction and renal failure resulting from prostate
lymphoma, and discuss the main clinical features of this rare neoplasia.
CASE REPORT
A
42-year old man was seen at our service, complaining of weak urinary stream
and dysuria for 10 days. Digital rectal examination showed a voluminous
prostate with fibroelastic consistency. Blood testes revealed PSA of 0.7
ng/mL and serum creatinine of 3.6 mg/dL.
An ultrasonography of the urinary tract
showed a 286-gram prostate with moderate bilateral uretero-hydronephrosis.
Nuclear resonance imaging was normal in thorax, but the abdominal and
pelvic scan evidenced a voluminous expansive and infiltrative lesion exclusive
of the prostate, with intense impregnation, measuring 10 x 8 cm (Figure-1),
bilateral uretero-hydronephrosis, and absence of lymph nodal involvement.
Bone scintigraphy was negative for secondary lesions. Patient evolved
to anuria, and subsequently underwent bilateral nephrostomy.
Prostate biopsy was performed, identifying
a diffuse large cell lymphoma, whose immunohistochemical test was positive
for antibodies CD45 (UCHL1–DAKO) and CD20 (L26–DAKO), characterizing
B-cell lymphoma (Figure-2). Using the King & Cox modified criteria,
the diagnosis of primary extranodal lymphoma of the prostate was confirmed
(stage IAE) (1).
Patient initiated cytotoxic chemotherapy
with cyclophosphamide, doxorubicin, vincristine and etoposide. After the
second cycle, he showed significant clinical and laboratorial improvement,
with spontaneous voiding and creatinine levels of 1.5 mg/dL.
COMMENTS
Approximately
one third of non-Hodgkin lymphomas occur in extranodal sites. Primary
lymphomas of the prostate represent 0.1% of cases, and many times, it
is incidentally found following prostate surgery for resolving bladder
obstruction (1).
Primary lymphomas of the prostate occur
in men aged 60 years in average. The most frequent presentation forms
are obstructive urinary symptoms, and obstruction can lead to renal failure
(1-3). The occurrence of systemic symptoms such as fever or weight loss,
identification of hepatosplenomegaly and inguinal lymphadenopathy on physical
examination, or changes in laboratory tests are uncommon. The digital
rectal examination can reveal an extremely enlarged prostate with normal
consistency, with unaltered PSA (2).
The definition of primary lymphoma of the
prostate is based in several criteria. The main symptoms are urinary,
the disease occurs predominantly in the prostate, with or without extension
to adjacent tissues and there is no involvement of lymph nodes, liver,
spleen or blood up to 1 month after diagnosis (3).
Several therapeutic modalities have been
reported, including prostatectomy, radiotherapy, chemotherapy, and even
cystoprostatectomy (1,2). However, the best therapeutic approach for primary
lymphoma of the prostate is chemotherapy based on doxorubicin (3). Among
the 23 cases of primary lymphoma of the prostate reported on the Japanese
literature, 3 of 5 cases treated with radiotherapy or radical prostatectomy
resulted in death or progression of disease. On the other hand, 11 out
of 16 cases (69%) that received chemotherapy alone or associated with
other treatments had a full response (3).
The authors conclude that prostate lymphomas,
despite being rare, must be included in differential diagnostic of cases
with obstruction of the lower urinary tract, especially in patients with
exaggerated enlargement of the gland and previous history of lymphoma
in other sites. Chemotherapy constitutes the primary therapeutic approach.
REFERENCES
- Sarris A, Dimopoulos M, Pugh W, Cabanillas F: Primary lymphoma of
the prostate: good outcome with doxorubicin-based combination chemotherapy.
J Urol. 1995; 153: 1852-4.
- Bostwick DG, Mann RB: Malignant lymphomas involving the prostate.
A study of 13 cases. Cancer. 1985; 56: 2932-8.
- Fukutani K, Koyama Y, Fujimori M, Ishida T: Primary malignant lymphoma
of the prostate: report of a case achieving complete response to combination
chemotherapy and review of 22 Japanese cases. Nippon Hinyokika Gakkai
Zasshi. 2003; 94: 621-5.
____________________
Received: July 20, 2004
Accepted after revision: August 12, 2004
_______________________
Correspondence address:
Dr. Alberto Azoubel Antunes
Rua Três de Maio, 17 / 31
São Paulo, SP, 04044-020, Brazil
E-mail: betoazoubel@yahoo.com.br |